Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nutramax To Sell Opthalmics Unit, Focus on First Aid, Cough/Cold, H&BAs

This article was originally published in The Tan Sheet

Executive Summary

Nutramax plans to divest its ophthalmics business, Optopics Laboratories, and shift its private label focus to the first aid business acquired in September 1997 for $40 mil. in cash, the Gloucester, Mass.-based private labeler announced April 27.

You may also be interested in...



NutraMax divestiture

OTC health products company is selling its Optopics Laboratories ophthalmics division to Miza Pharmaceuticals, the firm announces Oct. 15. NutraMax expects to finalize the deal within 35 days. The company announced in the spring its intention to sell the business to devote attention to its more profitable first aid, cough/cold and personal care lines (1"The Tan Sheet" May 3, p. 12). Optopics products include OTC eye drops, artificial tears and contact lens solutions and cleaners sold under brand names including Optopics, as well as eight Rx products. Acquired by NutraMax in 1993, the business recorded $11.6 mil. in revenues in fiscal 1998. Separately, NutraMax' common stock is delisted from the Nasdaq SmallCap Market because the company has not filed its 10-Q report for the fiscal third quarter and nine month periods ended July 3 with the SEC. NutraMax says it continues to work with its auditors to complete the filing but is unable to predict when it will be able to do so. The firm has cited inventory and accounting procedures as the reason for the delay (2"The Tan Sheet" Aug. 30, In Brief)

NutraMax divestiture

OTC health products company is selling its Optopics Laboratories ophthalmics division to Miza Pharmaceuticals, the firm announces Oct. 15. NutraMax expects to finalize the deal within 35 days. The company announced in the spring its intention to sell the business to devote attention to its more profitable first aid, cough/cold and personal care lines (1"The Tan Sheet" May 3, p. 12). Optopics products include OTC eye drops, artificial tears and contact lens solutions and cleaners sold under brand names including Optopics, as well as eight Rx products. Acquired by NutraMax in 1993, the business recorded $11.6 mil. in revenues in fiscal 1998. Separately, NutraMax' common stock is delisted from the Nasdaq SmallCap Market because the company has not filed its 10-Q report for the fiscal third quarter and nine month periods ended July 3 with the SEC. NutraMax says it continues to work with its auditors to complete the filing but is unable to predict when it will be able to do so. The firm has cited inventory and accounting procedures as the reason for the delay (2"The Tan Sheet" Aug. 30, In Brief)

NutraMax divestiture

OTC health products company is selling its Optopics Laboratories ophthalmics division to Miza Pharmaceuticals, the firm announces Oct. 15. NutraMax expects to finalize the deal within 35 days. The company announced in the spring its intention to sell the business to devote attention to its more profitable first aid, cough/cold and personal care lines (1"The Tan Sheet" May 3, p. 12). Optopics products include OTC eye drops, artificial tears and contact lens solutions and cleaners sold under brand names including Optopics, as well as eight Rx products. Acquired by NutraMax in 1993, the business recorded $11.6 mil. in revenues in fiscal 1998. Separately, NutraMax' common stock is delisted from the Nasdaq SmallCap Market because the company has not filed its 10-Q report for the fiscal third quarter and nine month periods ended July 3 with the SEC. NutraMax says it continues to work with its auditors to complete the filing but is unable to predict when it will be able to do so. The firm has cited inventory and accounting procedures as the reason for the delay (2"The Tan Sheet" Aug. 30, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel